35
Participants
Start Date
March 31, 2012
Primary Completion Date
January 31, 2014
Study Completion Date
December 31, 2015
Dovitinib (TKI258)
500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
University of Virginia Health System, Charlottesville
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
University of Virginia
OTHER